BSE filing, NSE: ISHITADR. Summary written from the filing by ALFA Finder's alert engine.
Ishita Drugs & Industries Ltd: key numbers
- Share price
- ₹73.30
- Market cap
- ₹21.92 Cr
- Revenue (annual)
- ₹14.66 Cr
- Net profit (annual)
- ₹0.78 Cr
- P/E (TTM)
- 31.0×Sector 45.9×
- Promoter holding
- 50.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ishita Drugs & Industries Ltd
All →Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries will hold a board meeting on 03/11/2026 to approve Q1 FY2027 unaudited results. The filing is a prior intimation under Regulation 29 of SEBI LODR.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd submitted its quarterly shareholding pattern under Regulation 31, disclosing the promoter and public shareholdings as of September 30, 2026.
Ishita Drugs & Industries Management Change
Ishita Drugs and Industries Limited has re-appointed Mrs. Abha Agrawal as a Non-Executive Non-Independent Director. The company also re-appointed M/s. Jaymin Shah & Associates as Statutory Auditors.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd has re-appointed M/s. Jaymin Shah & Associates as its Statutory Auditor from the 33rd to the 34th AGM.
Ishita Drugs & Industries Annual General Meeting
Ishita Drugs & Industries Ltd. held its 33rd Annual General Meeting on September 30, 2026. The meeting covered financial statements, auditor appointments, and director re-appointment.
Ishita Drugs & Industries Debt & Borrowing: ₹11.75 Cr
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
- Value
- ₹11.75 Cr
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.